TBPMF News and Press, Tetra Bio-Pharma Inc From 11/25/19

Company to resume clinical trial in advanced cancer patients with uncontrolled pain Tetra engages leading clinical collaborator to run Plenitude trial in the U.S. OTTAWA, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma   Inc., (TSX-V: TBP) (OTCQB: TBPMF),  a leader in...

OTTAWA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced its subsidiary, 2714140 Ontario Inc., has secured financing of CAD $3,000,000 in the form of conve...

OTTAWA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”) is pleased to announce that the Corporation has become a member of BIOTECanada, a national industry association with over 200 members that represents Canada’s health, ...

OTTAWA, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today confirmed its regulatory strategy of its CAUMZ TM (PPP011) inhalation drug product and provided additional updat...

Azevedos To Commercialize Awaye™ in Portugal, Tunisia and Mozambique in Q1 2020 Tetra to submit two non-prescription DIN applications in Canada Tetra to commercialize non-prescription drugs in USA OTTAWA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (&#x...

OTTAWA, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”) today provides an update on its initiatives to bring its Caumz ® (PPP011) inhalation drug product to the market.  The previous financing has allowed Tetra to ...

U.S. Food and Drug Administration (FDA) allows evaluation of CAUMZ Kit as a combination drug/device product, providing clarity on regulatory approval pathway This is a first step in the regulatory strategy to bring CAUMZ Kit to the market with additional FDA guidance anticipated by en...

OTTAWA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced it has signed an agreement with Thorne Research Inc. and Onegevity Health LLC to form a joint venture,...

ORLEANS, Ontario, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged LifeSci Advisors LLC, a leading investor relations consultancy serving life science companies, an...

ORLEANS, Ontario, July 30, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the  “Corporation”) is pleased to announce that, after successfully completing a prospectus offering for aggregate gross proceeds of $8,050,000 on July 12, 2019 (the &#x...